NextRNA Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
650 E Kendall St, Cambridge, Massachuset...Phone Number
(617) 412-6117Website
www.nextrnatx.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About NextRNA Therapeutics
Founded in 2021, NextRNA is a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics. The company is headquartered in Cambridge, Massachusetts.Explore more
NextRNA Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NextRNA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NextRNA Therapeutics
Click to see if NextRNA Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once NextRNA Therapeutics has new funding data
NextRNA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if NextRNA Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NextRNA Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NextRNA Therapeutics recently announced quarterly report
Check if NextRNA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to NextRNA Therapeutics
Compare insights from companies similar to NextRNA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NextRNA Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NextRNA Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NextRNA Therapeutics.
NextRNA Therapeutics financials insights
Gather financial insights about NextRNA Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$46.8M
Angel/Seed
$9.3M
NextRNA Therapeutics Tech Stack
A closer look at the technologies used by NextRNA Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Executive Move
Board of Directors
New Hire
Executive Move
Promotion
Executive Move
NextRNA Therapeutics News & Media
NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced the appointment of Jesse Smith, Ph.D., as Chief Scientific Officer (CSO). Dr. Smith brings to NextRNA over 20 years of drug discovery and development experience with a deep focus on advancing first-in-class targeted small molecule therapies. lncRNAs represent a vast class of therapeutic targets that recruitBayer partners with RNA drugmaker to develop new cancer therapies | BioPharma Dive
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced that they have entered into a collaboration and license agreement to develop small molecule therapeutics targeting lncRNAs in oncology. lncRNAs represent a vast class of therapeutic targets that recruit RNA-binding proteins (RBPs) to drive pathological processes across diseases. DisruptinNextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors. Dr. Friedman is currently Chief Scientific Officer of ORIC Pharmaceuticals, Inc. and formerly served as head of translational oncology for Genentech Research and Early Development (
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NextRNA Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2021, NextRNA is a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics. The company is headquartered in Cambridge, Massachusetts.... Read More
